These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

712 related items for PubMed ID: 16114787

  • 1. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R, Bhaduri S, Singh AK, PROMPT Study Group.
    Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
    [Abstract] [Full Text] [Related]

  • 2. Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease.
    Provenzano R, Singh AK.
    Endocr Pract; 2007 Aug; 13(3):251-9. PubMed ID: 17599856
    [Abstract] [Full Text] [Related]

  • 3. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M, Thimons DG, Winston JL, Langholff W, McGowan T.
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [Abstract] [Full Text] [Related]

  • 4. A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.
    Pergola PE, Gartenberg G, Fu M, Sun S, Wolfson M, Bowers P.
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):598-606. PubMed ID: 20185602
    [Abstract] [Full Text] [Related]

  • 5. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
    Henry DH, Gordan LN, Charu V, Wilhelm FE, Williams D, Xie J, Woodman RC.
    Curr Med Res Opin; 2006 Jul; 22(7):1403-13. PubMed ID: 16834839
    [Abstract] [Full Text] [Related]

  • 6. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.
    Pergola PE, Gartenberg G, Fu M, Wolfson M, Rao S, Bowers P.
    Clin J Am Soc Nephrol; 2009 Nov; 4(11):1731-40. PubMed ID: 19808215
    [Abstract] [Full Text] [Related]

  • 7. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review.
    Germain M, Ram CV, Bhaduri S, Tang KL, Klausner M, Curzi M.
    Nephrol Dial Transplant; 2005 Oct; 20(10):2146-52. PubMed ID: 15985516
    [Abstract] [Full Text] [Related]

  • 8. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease.
    Spinowitz B, Germain M, Benz R, Wolfson M, McGowan T, Tang KL, Kamin M, Epoetin Alfa Extended Dosing Study Group.
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1015-21. PubMed ID: 18400964
    [Abstract] [Full Text] [Related]

  • 9. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
    Montoya VP, Xie J, Williams D, Woodman RC, Wilhelm FE.
    Support Care Cancer; 2007 Dec; 15(12):1385-92. PubMed ID: 17541653
    [Abstract] [Full Text] [Related]

  • 10. Prevalence and treatment of anemia with once-weekly epoetin alfa in patients with diabetes and chronic kidney disease.
    Lorber DL, Provenzano R, McClellan W.
    Endocr Pract; 2006 Dec; 12(5):506-13. PubMed ID: 17002925
    [Abstract] [Full Text] [Related]

  • 11. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease.
    Provenzano R, Garcia-Mayol L, Suchinda P, Von Hartitzsch B, Woollen SB, Zabaneh R, Fink JC, POWER Study Group.
    Clin Nephrol; 2004 Jun; 61(6):392-405. PubMed ID: 15224803
    [Abstract] [Full Text] [Related]

  • 12. Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients.
    Grossman HA, Goon B, Bowers P, Leitz G, 010 Study Group.
    J Acquir Immune Defic Syndr; 2003 Dec 01; 34(4):368-78. PubMed ID: 14615654
    [Abstract] [Full Text] [Related]

  • 13. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P.
    Am J Nephrol; 2006 Dec 01; 26(2):149-56. PubMed ID: 16636531
    [Abstract] [Full Text] [Related]

  • 14. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
    Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, Inamoto A, Lillie T.
    BMC Cancer; 2010 Oct 25; 10():581. PubMed ID: 20973982
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr 25; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 16. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
    Papatheofanis F, Smith C, Mody S, McKenzie RS, Bookhart B, Piech CT.
    Am J Ther; 2007 Apr 25; 14(4):322-7. PubMed ID: 17667204
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of epoetin alfa administered every 2 weeks to maintain hemoglobin and quality of life in anemic HIV-infected patients.
    Levine AM, Salvato P, Leitz GJ, Champs 2 Study Group.
    AIDS Res Hum Retroviruses; 2008 Feb 25; 24(2):131-9. PubMed ID: 18284320
    [Abstract] [Full Text] [Related]

  • 18. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.
    Oncologist; 2004 Feb 25; 9(1):90-6. PubMed ID: 14755018
    [Abstract] [Full Text] [Related]

  • 19. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
    Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloëguen C, Beyer U, STRIATA Study Investigators.
    Nephrol Dial Transplant; 2008 Nov 25; 23(11):3654-61. PubMed ID: 18586762
    [Abstract] [Full Text] [Related]

  • 20. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
    Cartenì G, Giannetta L, Ucci G, De Signoribus G, Vecchione A, Pinotti G, Puglisi F, Contillo A, Pezzella G, Orecchia S, Beccaglia P, OBI/EPO-ITA-01/1 study group.
    Support Care Cancer; 2007 Sep 25; 15(9):1057-66. PubMed ID: 17431689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.